骨髓增生异常综合征患者p53功能障碍的特征及临床意义
该研究分析6204例骨髓增生异常综合征(MDS)患者,部分患者有RNA测序(n=109)、免疫细胞高维表型(n=77)和单细胞多组学(n=15)数据,并在914例中独立验证。双等位TP53失活是疾病进展的强力驱动因素,可识别高危患者;5%的MDS为TP53野生型但异常p53蛋白高表达,预后极差,伴上游信号异常和免疫失调。
要点
- 双等位TP53失活是MDS疾病进展的强力驱动因素,可识别高危患者。
- 单等位和双等位失活代表MDS伴TP53突变的多步过程阶段。
- 5%的MDS为TP53野生型但异常p53蛋白高表达,预后极差。
核心结论
- 识别MDS中非突变型p53功能障碍可能为髓系肿瘤的机制性分类奠定基础。
- 识别p53功能障碍患者有助于提供正确的疾病风险评估和干预,并优化临床试验设计。
研究设计与样本
- 分析6204例MDS患者队列,其中RNA测序可评估109例,免疫细胞高维表型可评估77例,单细胞多组学(RNA测序和蛋白质组学)可评估15例。
- 在914例患者中进行独立验证。
主要发现
- 双等位TP53失活是疾病进展的强力驱动因素,无论变异等位基因频率如何均可识别高危患者。
- 单等位和双等位失活代表MDS伴TP53突变的多步过程阶段。
- 5%的MDS为TP53野生型且骨髓祖细胞中异常p53蛋白高表达,预后极差。
- 这些患者存在上游p53信号异常,涉及Pi3K级联、RAS、WNT和NF-KB通路以及MDM2基因扩增,同时下游p53靶点失调。
- p53功能障碍的MDS显示独特的免疫失调,涉及髓系来源炎症和抗原呈递受损。
关键数值与推荐
- 双等位TP53失活可识别高危MDS患者,无论变异等位基因频率。
- 5%的MDS为TP53野生型伴异常p53蛋白高表达,预后极差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor. We aimed to characterize mutational and nonmutational mechanisms of p53 dysfunction in myelodysplastic syndromes (MDS) and to investigate their clinical effect. PATIENTS AND METHODS: We analyzed a cohort of 6,204 patients with MDS and subsets of patients with available information on RNA sequencing of tumor cells (n = 109), high-dimensional phenotype of immune cells (n = 77), and multiomics analysis (RNA sequencing and proteomics) on single cells (n = 15). An independent validation was performed on 914 patients. RESULTS: Biallelic TP53 inactivation was a powerful driver of disease progression and identified high-risk patients, regardless of variant allele frequency. Monoallelic and biallelic inactivation represent disease stages occurring as a multihit process in MDS with TP53 mutations, thus potentially refining the optimal timing of therapeutic interventions in these patients. We identified a subset of MDS (5%) characterized by TP53 wild-type and hyperexpression of abnormal p53 protein in bone marrow progenitors that exhibit dismal outcome. These patients presented upstream p53 signaling aberrations in Pi3K cascade; RAS, WNT, and NF-KB pathways; and MDM2 gene amplification, together with a downstream dysregulation of p53 targets. MDS with p53 dysfunction displayed a distinct immune dysregulation involving myeloid-derived inflammation and impaired antigen presentation, which may be a driver of their poor prognosis and provide the groundwork for innovative immunotherapies. CONCLUSION: The identification of nonmutational p53 dysfunction in MDS may lay the foundation for a mechanistic classification of myeloid neoplasms, moving beyond a purely molecular stratification. The recognition of patients with p53 dysfunction is relevant to provide correct disease-risk assessment and interventions, as well as to refine the design of clinical trials.
引用
- Zampini M, Riva E, Lanino L, et al. Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes. J Clin Oncol. 2025. PMID: 40315418. doi:10.1200/JCO-24-02394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。